Focus: Aurigene is a Bangalore-based drug discovery biotechnology company founded in 2001, focused on oncology and immunology therapeutics. The company operates as a public entity with a pipeline-driven business model centered on novel small molecule and biologic development.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Aurigene to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aurigene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Aurigene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Aurigene to invest $100 M across Small Molecules, Peptides, Neutraceuticals and Biologics - BioSpectrum India
Aurigene to invest $100 M across Small Molecules, Peptides, Neutraceuticals and Biologics BioSpectrum India
Aurigene bets big on CRDMO expansion with $100 million outlay - Indian Pharma Post
Aurigene bets big on CRDMO expansion with $100 million outlay Indian Pharma Post
Aurigene Pharma collaborates with Alveus Therapeutics to advance peptide and small molecule programmes for metabolic diseases - BioSpectrum India
Aurigene Pharma collaborates with Alveus Therapeutics to advance peptide and small molecule programmes for metabolic diseases BioSpectrum India
Bioinformatics Job at Aurigene Pharmaceutical | Apply Now - BioTecNika
Bioinformatics Job at Aurigene Pharmaceutical | Apply Now BioTecNika
Tushar Zade appointed Chief Transformation Officer at Granules India, strengthening digital and pharma leadership - CXO Digitalpulse
Tushar Zade appointed Chief Transformation Officer at Granules India, strengthening digital and pharma leadership CXO Digitalpulse
8-K Filing: CURIS INC (CRIS) (CIK 0001108205) — EX-99.1
EX-99.1
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo